Tuesday, January 19, 2021

Investor Ideas #Potcasts 519, #Cannabis News and #Stocks on the Move; (CSE: $CRFT.C) (TSX.V: $WMD.V) (TSX: $WLLW.TO) (CSE: $IPOT.C)

 



 

Investor Ideas #Potcasts 519, #Cannabis News and #Stocks on the Move; (CSE: $CRFT.C) (TSX.V: $WMD.V) (TSX: $WLLW.TO) (CSE: $IPOT.C)

 

Delta, Kelowna, BC, January 19, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/011921-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/01191CRFT-WMD-WLLW-IPOT.asp

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be looking at a few public company announcements.

 

BC Craft Supply Co. Ltd. (CSE: CRFT) (OTC:CRFTFannounced that it entered into a binding letter of intent on January 15, 2021, to acquire 100% of the issued and outstanding shares of Ava Pathways Inc., from arm’s length parties .

 

Based in Vancouver, BC, Ava Pathways is an innovative company that is exploring the therapeutic scientific benefits of proprietary formulations, using compounds from mushrooms.  Ava Pathways was founded by scientists and researchers focused on neuroplasticity and alternative ways to treat common and debilitating medical conditions such as depression, anxiety, PTSD, and substance use disorder, through the use of psychedelic-based treatments. Similar to craft cannabis, both plant-based treatments require a cultivation supply network to create proprietary strains that produce optimal results for the patient or end-user.  Ava Pathways brings exceptional access to tested and standardized naturally-derived and synthetic materials which allows for the production of superior psychoactive and non-psychoactive formulations. 

BC Craft has been a pioneer in the craft cannabis sector since pre-legalization and continues that mission by acting as a comprehensive solution partner to other plant-based craft companies while advocating on their behalf.  Ava Pathways embodies that same compassionate mentality with the end-users well-being in mind.  Ava Pathways has over twenty collective years of experience and relationships in strong pre-clinical and clinical experimental programs that aim to provide patient and data-driven treatment through a robust clinical treatment network, which combine holistic and personalized treatment plans, therapy and education. Ava Pathways is headed up by CEO Dr. Lily Aleksandrova, a published expert in the field; Dr. Aleksandrova completed her Ph.D. in Neuroscience at UBC and boasts 10+ years of research experience in neuroscience, pharmacology and clinical research labs investigating novel neuropsychiatric treatments.

 

Matthew Watters, CEO of BC Craft stated, “We are delighted by the opportunity to bring Dr. Lily Aleksandrova and Ava Pathways into the BC Craft family, and into the long-term strategic direction of the Company which seeks to commercialize high-end artisanal brands in the cannabis industry, and in the emerging psychedelic space when the legal framework should allow." Mr. Watters goes on to state, “The LOI with Ava Pathways comes at an opportune time whereby the use of psychedelic compounds such as psilocybin in functional medicine has gained widespread and scientifically backed support from researchers as well as an increased social acceptance from the broader population.”

 

WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMFannounced that it is kicking off 2021 with the development of new extract products featuring live resin and solventless hash, and rosin concentrates. The Company’s newest Cannabis 2.0 extract products are expected to debut during the second quarter of 2021, under WeedMD’s Color Cannabis and Saturday Cannabis adult-use brands.

 

“WeedMD’s genetic library boasts unique strains, with flavour and aroma profiles widely recognized throughout the industry and we are thrilled to announce we are now expanding into high-value, terpene-rich hash, live resin and rosin products,” said George Scorsis, Executive Chairman and Interim CEO, WeedMD. “We are listening to our consumers and retail partners in developing these products and extending our portfolio. Our cultivation, commercial and product teams are now capturing these profiles in a variety of formats including solventless concentrates and extracts to deliver premium products under our Color and Saturday Cannabis brands. This expanded portfolio is tailor-made for consumers looking for richer cannabis concentrates and alternative cannabis consumption methods.”

 

Product development for both solventless cannabis concentrates (including bubble hash and rosin) and hydrocarbon (live resin) extract products is currently underway alongside WeedMD and its highly skilled third-party processors. This includes trialing processes to produce extracts which best capture and preserve the Company’s most robust, trichome-coated flowers, including award-winning strains such as Pedro’s Sweet Sativa and Mango Haze.

 

The Company has further developed a unique, in-house sub-critical CO2 extract post-processing methodology, which preserves the flower’s terpene profile and results in a malleable, semi-solid high-potency cannabis extract product. Trials to confirm scalability and product integrity are currently underway at the Company’s Aylmer, Ontario processing and extraction hub.

Extract products will be produced using WeedMD’s own biomass, grown on site at the Company’s state-of-the-art greenhouse and outdoor field in Strathroy, Ontario. Initial new extract products are anticipated for market release in Q2 2021.

 

Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSFannounced that it has advanced its work on its proprietary yeast strain for production of Tetrahydrocannabinol ("THC"), and plans to commercially launch in the Canadian market.

 

"We are excited to announce our proprietary THC yeast biosynthesis production process for launch in the Canadian market," said Trevor Peters, Willow's President and Chief Executive Officer. "Our platform technology enables us to produce a variety of cannabinoids and leverage our previous work on CBG. From conversations with prospective customers in Canada, we believe that there is significant demand for consistent, high-purity THC. The flavourless, odorless attributes of our finished product make it suitable as a core ingredient for the cannabis 2.0 market in Canada. There is also strong demand for a more sustainable and environmentally friendly way to produce THC. Our manufacturing process is 50 to 500 times more efficient than indoor cultivation and is the next evolution of sustainable cannabinoid manufacturing."

 

The Company's Canadian based research and development group has developed a proprietary yeast strain and process for the production of THC and is working toward a pilot scale run later this year. While there is already a well-established market for THC in Canada, the Company believes there is significant demand from consumer product manufacturers looking for a consistent, high-purity, odorless, flavourless THC ingredient like Willow's for the 2.0 market, which consists of vapes, edibles, beverages, concentrates and topicals. The THC market for 2.0 products is already a multi-billion-dollar, multi-ton addressable market for Willow to sell into. The Company has identified a development partner for product isolation, purification and scale up to pilot and is in talks with several manufacturing companies in Canada to serve the adult-use market.

 

Willow will launch its THC into the Canadian adult-use market first due to its highly-regulated, legal and developed status. The Company is carefully watching the developments in the United States surrounding potential legalization and will be ready to react to any positive regulatory changes should they arise.

 

Isracann Biosciences Inc.  (CSE: IPOT) (OTC: ISCNF) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer, provided a year end summary of activities and outlook for 2021.

 

There is a sense of relief that 2020 is now behind us. Over the course of the past year, the impact of COVID-19 has been felt around the globe and will undoubtedly continue to impact countless lives and entire economies for years to come. While many difficulties remain before us all, a guarded optimism is growing daily. The challenges that directly impacted our venture were principally logistical and operational in nature and affected most of the sector equally. Given the Israeli governments increasingly pragmatic outlook regarding cannabis we remain extremely optimistic regarding our ability to achieve our strategic goals for the new year.

 

In consideration of the disruptive nature of the pandemic, Isracann is nonetheless extremely pleased to have made continued progress at both its domestic operations. At our early-stage Nir, Israel farm, the Company was required to realign elements of its submission to the Settlement Commissioner for the Nir region, which was expedited via the invaluable aid of our regional consultants. This process has paved the way for a formal application to the Ministry of Health. In all other respects the project is poised for fast-tracked completion with commencement of operations to occur as soon as approval is received.

 

The agreement and commitment to accelerate the completion of the flagship Hefer Valley-based Ein Hahoresh Farm has proven to be a key driver for the Company. With 165,000 sq. ft. of greenhouse canopy and extensive processing capability in-place, the Company and its regional partners are moving rapidly towards industrial-scale operations capable of servicing both the domestic and increasingly important European export markets in 2021.

 

Per recently amended regulations that require all physical facilities to be completed and approved prior to planting, the construction activities at the Ein Hahoresh farm expanded the onsite post-harvest facility in preparation for commencement of operations and increased demand from growing domestic and export markets. We are well poised to, in the short term, complete the facility and receive the required Security and Ministry of Health approvals to acquire our farm operating license and start planting. Consequently, Isracann and its local consultants are currently scheduling the commencement of planting in March to coincide with the start of optimal climatic conditions. Additionally, applications for certification of Isracann as foreign cannabis cultivation license owners were submitted to the Ministries of Security and Health, which upon acceptance, will result in Isracann’s ability to formally complete any remaining aspects of our joint venture acquisition.

 

While completion of our farms is the primary focus of the company, we have been actively initiating and expanding our visibility and relationships across the region and onwards into Europe. Our goal has been to establish infrastructural agreements aimed at launching Isracann onto the world stage as a truly international cannabis enterprise. As these pending activities are commercial in nature, and include multiple parties, we look forward to announcing further details outlining our expanded strategic outlook for the coming year as soon as possible.

 

Concurrently, the domestic legislative, regulatory, and societal environment regarding cannabis production, processing, distribution, and sales within Israel continues to improve as do the opportunities for export operations. Last year saw several landmark rulings and accelerated momentum that is rapidly transforming this emerging sector into a respected national industry.

 

It is also worth mentioning that Israel has been noted as an early leader in the distribution of coronavirus vaccinations, and this appears to be driving optimism for the entire business community throughout the region. Isracann and its team of professional consultants are confident this will aid initial sales projections upon entry into a domestic marketplace which is markedly more robust than ever before.

 

Company CEO Darryl Jones comments, “Since our decision to enter the market sector in Israel just 20 short months ago, we have seen cannabis reform, including major advances in legalization, production and distribution. We’ve also seen the door opening up for export sales, and a wholesale shift in cultural acceptance. And yet we have had to deal with some setbacks as the regional governments come to terms with new regulations and the impact of a global pandemic. But one thing to remember is that this is just the playing field, and it is the same field for everyone in the sector. As players, we have engaged top industry professionals to consult on our behalf, incorporated leading agronomic experts to show us the true path to product excellence, and ensured our leadership includes a strong mix of business and production expertise. We have a team with big league knowhow and home field advantage, and this all translates into ability and confidence. We are well positioned and well financed and are committed to ensuring that 2021 is the year Isracann gets fully into the game and starts to deliver the returns we know its capable of. With that vision firmly in-place, we thank all our supporters for your continued trust as we forge ahead to make this year an outstanding opportunity for value creation through the intelligent application of capital into predictably growth-focused areas of the global cannabis industry.”

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

No comments:

Post a Comment